June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Congress scientific sessions in Vienna, Austria.
KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).1
Data being presented at ERA include:
- Effect of Finerenone on eGFR Slope Across Different Levels of Baseline Albuminuria: Insights from FINEARTS-HF
- THE COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a UACR Endpoint (CONFIDENCE) TRIAL: Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes
- Changes in Albuminuria and The Effect of Finerenone on Cardiovascular Outcomes: Insights from FINEARTS-HF
For more information, go to www.bayer.com.
1. Bayer Pharmaceuticals. Kerendia (finerenone) [package insert]. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf. Accessed June 2, 2025.
June 25, 2025 
